Warning Letter Wednesday Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
Dangerous products will be cited even if they do not contain disease claims
Takeaway -
Use FDA’s helpful resource (criterion 6)
Takeaway -
Here are tips on using FDA’s ingredient directory
Takeaway -
Extra attention is paid to animal CBD products
Takeaway -
Learning from others' mistakes helps you be compliant
Takeaway -
Ensure statements are not disparaging
Takeaway -
Use FDA's helpful resource (Criterion 7)
Takeaway -
OTC Topical “Inactive” Ingredient Marketing Claims “Extra” claims are often non-compliant
Takeaway -
Use FDA’s helpful resource (Criterion 2)
Takeaway -
A look at the manufacturing and quality process
Takeaway -
Brands should monitor influencer posts for compliance
Takeaway -
Curated testimonials are marketing claims